GenVec Inc. Begins Phase II Melanoma Study With TNFerade(TM)

GAITHERSBURG, Md.--(BUSINESS WIRE)--March 29, 2006--GenVec, Inc. (Nasdaq:GNVC) has begun a Phase II clinical study to evaluate the anticancer activity of TNFerade(TM) in patients with metastatic melanoma. The open-label, single-arm, multi-center study will assess tumor response after four weeks of intratumoral injections of TNFerade(TM) plus concomitant radiation therapy in 29 patients with stage III or IV metastatic melanoma who are ineligible for curative surgery or unlikely to benefit from other treatment options. Patients will be evaluated two months after the completion of therapy and followed for three years thereafter.